Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID R
Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D Day
09:41am, Wednesday, 28'th Aug 2024
Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September 10 featuring discussions on the company's lead drug asset vidoflud
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
06:30am, Wednesday, 28'th Aug 2024
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
06:55pm, Friday, 09'th Aug 2024
Immunic, Inc. (NASDAQ:IMUX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Jessica Breu - VP, IR & Communications Daniel Vitt - CEO Glenn Whaley - CFO Jason Tardio -
Immunic strengthens leadership team as MS trials advance toward key milestones
09:10am, Thursday, 08'th Aug 2024
Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and the subsequent period. The biotechnology firm has welcome
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06:30am, Thursday, 08'th Aug 2024
– Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President – – Strengthened Board of Dire
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
06:30am, Thursday, 01'st Aug 2024
– Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally adm
Immunic chief scientific officer shares insights on innovative MS therapy - ICYMI
11:17am, Saturday, 27'th Jul 2024
To mark World Brain Day on July 22, Immunic Inc (NASDAQ:IMUX)'s chief scientific officer Hella Kohlhof joined Proactive to discuss the company's lead asset vidofludimus calcium which is being develope
Immunic appoints Simona Skerjanec to board of directors
09:20am, Wednesday, 24'th Jul 2024
Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors. Skerjanec brings nearly three decades of experience in drug development and commer
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
08:33am, Tuesday, 09'th Jul 2024
Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal efforts to prepare for the potential launch of v
Immunic Appoints Jason Tardio as Chief Operating Officer and President
06:30am, Tuesday, 09'th Jul 2024
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinica
Immunic to Participate in Industry and Scientific Conferences in June
06:30am, Tuesday, 28'th May 2024
NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
06:00am, Thursday, 23'rd May 2024
Penny stocks with insider buying addresses a key lingering concern among speculators: do the folks that are selling me their business actually believe in their business? I'm telling you, there's nothi
Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases
06:00am, Monday, 20'th May 2024
Nvidia Corp is set to dominate market discussions this week as it prepares to release its earnings report on Wednesday afternoon. The semiconductor giant, with a market cap of approximately $2.3 trill
Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript
02:20pm, Wednesday, 08'th May 2024
Immunic, Inc. (NASDAQ:IMUX ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President, Investor Relations & Communications Daniel Vitt - Chief Executi
